289 related articles for article (PubMed ID: 2154462)
21. Characterization of plasminogen activation by glycosylphosphatidylinositol-anchored urokinase.
Lee SW; Ellis V; Dichek DA
J Biol Chem; 1994 Jan; 269(4):2411-8. PubMed ID: 8300567
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the binding of urokinase-type plasminogen activator (u-PA) to plasminogen, to plasminogen-activator inhibitor-1 and to the u-PA receptor.
Lijnen HR; De Cock F; Collen D
Eur J Biochem; 1994 Sep; 224(2):567-74. PubMed ID: 7925373
[TBL] [Abstract][Full Text] [Related]
23. Binding of human single chain urokinase to Chinese Hamster Ovary cells and cloning of hamster u-PAR.
Fowler B; Mackman N; Parmer RJ; Miles LA
Thromb Haemost; 1998 Jul; 80(1):148-54. PubMed ID: 9684801
[TBL] [Abstract][Full Text] [Related]
24. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
25. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Apr; 262(12):5682-9. PubMed ID: 3106341
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
27. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator.
Lijnen HR; Van Hoef B; Collen D
Biochim Biophys Acta; 1986 Dec; 884(3):402-8. PubMed ID: 3778931
[TBL] [Abstract][Full Text] [Related]
28. Expression of an anchored urokinase in the apical endothelial cell membrane. Preservation of enzymatic activity and enhancement of cell surface plasminogen activation.
Lee SW; Kahn ML; Dichek DA
J Biol Chem; 1992 Jun; 267(18):13020-7. PubMed ID: 1535628
[TBL] [Abstract][Full Text] [Related]
29. Interaction of wild-type and catalytically inactive mutant forms of tissue-type plasminogen activator with human umbilical vein endothelial cell monolayers.
Ramakrishnan V; Sinicropi DV; Dere R; Darbonne WC; Bechtol KB; Baker JB
J Biol Chem; 1990 Feb; 265(5):2755-62. PubMed ID: 2105933
[TBL] [Abstract][Full Text] [Related]
30. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
[TBL] [Abstract][Full Text] [Related]
31. The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1.
Sarubbi E; Nolli ML; Robbiati F; Soffientini A; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):927-33. PubMed ID: 2512681
[TBL] [Abstract][Full Text] [Related]
32. Urokinase synthesis and binding by glomerular epithelial cells in culture.
Rondeau E; Ochi S; Lacave R; He CJ; Medcalf R; Delarue F; Sraer JD
Kidney Int; 1989 Oct; 36(4):593-600. PubMed ID: 2554052
[TBL] [Abstract][Full Text] [Related]
33. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
Pannell R; Gurewich V
Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
[TBL] [Abstract][Full Text] [Related]
34. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
[TBL] [Abstract][Full Text] [Related]
35. Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.
Tabengwa EM; Grenett HE; Benza RL; Abou-Agag LH; Tresnak JK; Wheeler CG; Booyse FM
Alcohol Clin Exp Res; 2001 Feb; 25(2):163-70. PubMed ID: 11236828
[TBL] [Abstract][Full Text] [Related]
36. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
37. Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells.
Nguyen G; Li XM; Peraldi MN; Zacharias U; Hagège J; Rondeau E; Sraer JD
Kidney Int; 1994 Jul; 46(1):208-15. PubMed ID: 7933839
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor-binding protein activates soluble and receptor-bound single chain urokinase-type plasminogen activator.
Wolf BB; Brown MD
FEBS Lett; 1995 Dec; 376(3):177-80. PubMed ID: 7498536
[TBL] [Abstract][Full Text] [Related]
39. Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin.
Abercrombie DM; Buchinski B; Salvato KA; Vovis GF; Stump DC; Broeze RJ
Thromb Haemost; 1990 Nov; 64(3):426-32. PubMed ID: 2128973
[TBL] [Abstract][Full Text] [Related]
40. The urokinase receptor is a major vitronectin-binding protein on endothelial cells.
Kanse SM; Kost C; Wilhelm OG; Andreasen PA; Preissner KT
Exp Cell Res; 1996 May; 224(2):344-53. PubMed ID: 8612711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
